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We report an association of single-nucleotide polymorphisms (SNPs) for the VSNL1 gene (visinin-like 1) with schizophrenia and
frontal cortical function in a sample of patients with Diagnostic and Statistical Manual of Mental Disorder-IV (DSM-IV) diagnoses
of schizophrenia, compared with healthy controls. Moreover, VSNL1 SNPs were associated with performance in the Wisconsin
Card Sorting Test, a measure for the assessment of frontal cortical function. The VSNL1 gene product, Visinin-like-protein-1
(VILIP-1), is a member of the neuronal EF-hand Ca
2þ-sensor protein family. Previously, VILIP-1 mRNA and protein expression
were shown to be altered in animal models and in schizophrenia patients. VILIP-1 inﬂuences cytosolic cyclic adenosine mono
phosphate (cAMP) levels, cell migration, exocytotic processes and differentiation in the periphery. This raises the question,
whether, similar to other potential schizophrenia susceptibility genes such as Disc1, PDE4B and Akt, VSNL1 may affect cAMP
signaling and neurite outgrowth in neurons. In dissociated rat hippocampal neurons, VILIP-1 small interfering RNA knockdown
decreased cAMP levels and reduced dendrite branching, compared with control-transfected cells. In contrast, VILIP-1
overexpression had the opposite effect. Similar results have been obtained in the human dopaminergic neuronal cell line SH-
SY5Y, where the effect on neurite branching and length was attenuated by the adenylyl cyclase inhibitor 20,50-dideoxyadenosine
andtheproteinkinaseAinhibitorKT5720.TheseresultsshowthattheassociationofVSNL1SNPswiththediseaseandcognitive
impairments, together with previously observed pathological changes in VILIP-1 protein expression, possibly occurring during
brain development, may contribute to the morphological and functional deﬁcits observed in schizophrenia.
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Introduction
Schizophrenia is a major disabilitating psychiatric disorder
affecting approximately 1% of the population worldwide. The
developmental disease originates from disturbances in very
complex combination of genetic information, as well as
environmental factors.
1,2 About 2.2 million US citizens are
diagnosed with schizophrenia, which, due to its early onset,
results in an estimated cost for society of approximately $60
billion annually.
3 Pathological ﬁndings, including reduced
interneuronal space and dendritic differentiation, decrease
in dendritic markers, and a reduction in dendritic length,
4–7
provide neuroanatomical evidence for the observed aberrant
connectivitybetweenbrainstructures,whichmaybetheorigin
of psychotic symptoms and cognitive deﬁcits. The consistent
ﬁndings of ventricular enlargement and decreased brain
volume in the hippocampus and cortex may be explained by
decreases in dendrites and axons, a hypothesis known as the
‘reduced neuropil hypothesis’.
4,8 Thus, it is likely that the
underlying cellular mechanisms of the disease comprise
developmental changes in the differentiation of dendritic and
axonal structures of neurons. Indeed, growth factors, such as
brain-derived neurotrophic factor and insulin-like growth
factor-1 affecting neuronal differentiation, have a role in
schizophrenia.
9,10 Former identiﬁed putative susceptibility
genes for schizophrenia, such as NRG1, Akt1, dysbindin-1
and DISC-1 have all been implicated in neuronal differentia-
tion and neurite formation in cellular and animal models of
neurodevelopment.
8,11–13 Disrupted in schizophrenia 1
(DISC1) is one of the most convincing genetic risk factors
for major mental illness identiﬁed to date. DISC1 interacts
directly with cyclic adenosine mono phosphate (cAMP)-
hydrolyzingenzymephosphodiesterase4B,anindependently
identiﬁed risk factor for schizophrenia.
14 Moreover, the cAMP
signaling pathway is implicated in shaping neuronal morphol-
ogy during development.
15
Different linesofevidencehaveaccumulatedindicatingthat
neuronalcalciumsensorproteins,suchasvisinin-like-protein-1
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calciumsensor-1,areassociatedwithschizophrenia.Neuronal
calcium sensor proteins are key players in different neuronal
signaling pathways
16,17 and are implicated in numerous
pathological processes of central nervous system disorders.
18
Recent genome-wide linkage studies in the Korean population
have shown association of chromosome 2p24.3 with schizo-
phrenia, where the VSNL1 gene lies.
19 VSNL1 has also been
correlatedwithcytoarchitecturalabnormalitiesinschizophrenia
and bipolar depression in the US population, with a differ-
entiated gene expression found in the frontal cortex,
20
identifying VSNL1 as a possible novel susceptibility factor.
Earlier data from post-mortem studies in schizophrenic
patients and in a ketamine schizophrenia model, revealed
already reduced numbers and staining intensity of pyramidal
neurons positive for the gene product VILIP-1.
21–23 These
results have been conﬁrmed independently by microarray and
proteomic studies.
24,25 More recently, increased expression of
microRNAs (for example, miR-181b) was discovered in
schizophrenia and was found to negatively regulate VILIP-1
expressioninschizophrenicbrainsandinhumandopaminergic
SH-SY5Y neurons,
26 further adding to evidence implicating
VILIP-1 in schizophrenia. Interestingly, insulin and IGF-1,
which have also been associated with schizophrenia,
increases the expression of genes that show pathological
decrease in expression in schizophrenia, including VILIP-1
expression, in human SH-SY5Y model neurons.
27
Originally, VSNL1, which is highly conserved between
chick, mouse and human, was identiﬁed during a screen for
developmentally upregulated genes in the chick visual cortex,
where it shows enhanced expression levels during neuronal
differentiation and axonal pathﬁnding.
28 In vitro assays have
shown that the protein upregulates cAMP levels and
differentiation in various peripheral cells, such as pancreatic,
kidney, skin and glioma cells.
29–32 Interestingly, in mouse
b-cells, overexpression of VILIP-1 increases cAMP, which is
accompanied by increased cAMP-responsive element-bind-
ing protein gene expression.
31 Moreover, in squamous cell
carcinoma, VILIP-1 inhibits rhoA via elevating cAMP levels.
32
The cAMP pathway and cAMP-responsive element-binding
protein activation, as well as inhibition of the rhoA-ROCK
pathway, have been implicated in promotion of neurite
outgrowth and functional recovery of neurons.
15,33 Thus, we
speculatethatVILIP-1,inconjunctionwiththecAMPpathway,
has a role for neuronal differentiation.
The speciﬁc aims of the study were to evaluate whether
VSNL1 single-nucleotide polymorphisms (SNPs) show asso-
ciation with schizophrenia, and especially associate with one
of the most sensitive measures for assessing impaired frontal
cortical function, the Wisconsin Card Sorting Test (WCST).
34
We next asked what the functional impact of VSNL1 SNPs
and pathological expression of VILIP1 might be for neurode-
velopment. Therefore, we have investigated whether VILIP-1
can inﬂuence cAMP signaling in neurons and have started to
decipher its effect on neuronal morphology.
Materials and methods
Materials. Recombinant nerve growth factor and siRNA for
VILIP-1 and control small interfering RNA (siRNA) were
obtained from Invitrogen (Carlsbad, CA, USA). Forskolin,
DDA (20,50-dideoxyadenosine), H89 and KT5720 were from
Tocris Biosciences (Ellisville, MO, USA) or from Sigma
(St Louis, MO, USA). SMI-312 was from Covance (Austin,
TX, USA). Afﬁnity puriﬁed antibody against VILIP-1 was
described previously.
35
Cell culture and transfection of hippocampal
neurons. Hippocampal cultures were prepared from fetal
wistar rat brains (E18) and cultured as previously
described.
35 Cells were plated onto poly-D-lysin coated
12-well culture plates at a density of 120000 cells for
transient transfection experiments and onto 24-well culture
plates with glass coverslips at a density of 60000 cells for
immunocytochemistry. After 24h of plating, culture medium
was exchanged for neurobasal medium/b27 medium
(Invitrogen), and hippocampal neurons were transfected
after 1 day in culture with complementary DNA for green
ﬂuorescent protein (GFP), VILIP-1-GFP
35 or siRNA, using
the lipofectamin transfection method (Invitrogen) and
cultured for 48h.
Cell culture and transfection of SH-SY5Y cells. SH-SY5Y
cells were from ATCC (ATCC Number: CRL-2266, Salt Lake
City, UT, USA) and cultured according to the suppliers
instructions. For neurite outgrowth assays, 9000 SH-SY5Y
cells were placed in each 24-well cell culture plate
with media containing 10% fetal bovine serum for 24h,
followed by neurobasal/B27 medium. After 4h of incubation,
different chemicals were added to study the speciﬁc
pathways involved (nerve growth factor and KT5720,
100nM; DDA, 300mM) for an additional 48h. The Amaxa
nucleofector system (Lonza, Cologne, Germany) was used
for transfection with GFP and GFP-VILIP-1, or siRNA
knockdown experiments with siRNA for VILIP-1 and
scrambled control siRNA. Transfection efﬁciency was
measured by counting percentage of cells showing green
ﬂuorescence, using a confocal microscope (TCS SPE, Leica
Microsystems, Buffalo Grove, IL, USA).
Cell morphology analysis. Photographs of hippocampal
neurons and SH-SY5Y neurons were analyzed with the
Image J software (version1.41, NIH, http://rsb.info.nih.gov/ij/
index.html) using the Sholl and neuron J plugin. For Sholl-
analysis, quantiﬁcation of transfected hippocampal neurons
was performed by counting the number of neurite
intersections of concentric circles placed around the center
of the cell soma in gradually increasing radii from 20 to
100mm. For SH-SY5Y cells, number and length of neurites
longer than the diameter of one cell were measured using the
neuron J plugin.
Western blot analysis. Hippocampal neurons (60000) or
SH-SY5Y cells (10000) were cultured in 12-well cell culture
plates for western blot analysis. After 48h of transfection, the
cells were lysed, and western blot analysis using primary
anti-VILIP-1 antibody or anti-actin antibody for control was
performed as previously described.
35
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Translational PsychiatryCyclic AMP assay. The production of cyclic adenosine
mono phosphate (cAMP) was measured using the
Amersham enzyme immunoassay kits (EIA 225,
Amersham, Uppsala, Sweden) or the Cisbio HTRF c-AMP
kit (Cisbio, Bedford, MA, USA) for hippocampal neurons and
SH-SY5Y neurons, respectively. Transfected cells (60000
hippocampal neurons, 30000 SH-SY5Y neurons) were
analyzed following the manufacturers’ protocols.
Schizophrenic patients. A total of 627 individuals with
schizophrenia were ascertained from the Munich area in
Germany. Of them, 66% were of German descent (that is,
both parents were German) and 34% were other Caucasians
from middle Europe. Case participants had a DSM-IV
and International Classiﬁcation of Disease-10 (ICD-10)
diagnosis of schizophrenia with the following subtypes:
paranoid 78%, disorganized 15%, catatonic 2% and
undifferentiated 5%. Detailed medical and psychiatric
histories were collected, including the Structured Clinical
Interview for DSM-IV (SCID), to evaluate lifetime axis I and II
diagnoses.
36,37 All details of this group of schizophrenic
patients have been published elsewhere.
38 Four physicians
and one psychologist rated the SCID interviews and all
measurements were double rated by a senior researcher.
Exclusion criteria included a history of head injury or
neurological diseases. All case participants were outpatients
or stable inpatients.
Healthy controls. A total of 541 unrelated volunteers of
German descent (that is, both parents German) were
randomly selected from the general population of Munich,
Germany, and contacted by mail. To exclude subjects with
central neurological diseases and psychotic disorders or
subjects who had ﬁrst-degree relatives with psychotic
disorders, several screenings were conducted before the
volunteers were enrolled in the study. First, subjects who
responded were initially screened by phone for the absence
of neuropsychiatric disorders. Second, detailed medical and
psychiatric histories were assessed for both themselves and
their ﬁrst-degree relatives by using a semi-structured
interview. Third, if no exclusion criteria were fulﬁlled, they
were invited to a comprehensive interview including the
SCID I and SCID II
36,37 to validate the absence of any
lifetime psychotic disorder. Additionally, the Family History
Assessment Module
39 was conducted to exclude psychotic
disorders among their ﬁrst-degree relatives. Furthermore, a
neurological examination was conducted to exclude subjects
with current central nervous system impairment. In the case
that the volunteers were older than 60 years, the Mini-Mental
Status Test
40 was performed to exclude subjects with
possible cognitive impairment. Written informed consent
was obtained from all subjects after a detailed and
extensive description of the study, which was approved by
the local ethics committee and carried out in accordance to
the ethical standards laid down in the Declarations of
Helsinki.
Wisconsin card sorting test. A subset of the patients and
controls were further characterized. A total of 566 (353
healthy volunteers, 213 patients) subjects participated in the
WCST (Computer Version 4),
41 where cards have to be
sorted against a set of four standard cards according to a
certain unknown rule, such as color, shape or number of
symbols on the cards. Sorting rules changed according to
predeﬁned criteria.
Genotyping. DNA extraction was done with the QIAamp
Blood Maxi Kit (QIAamp DNA Blood Midi/Maxi Handbook,
Firma Qiagen, Hilden, Germany, 2005). DNA concentration
was adjusted using the PicoGreen quantitation reagent
(Invitrogen, Karlsruhe, Germany). The samples were
genotyped using the Illumina HumanHap300 BeadChip
according to the manufacturer’s speciﬁcations (Illumina,
San Diego, CA, USA). All solutions and reagents are from
Illumina and were used according to the manufacturer’s
speciﬁcations. Several quality checks for genome-wide
studies, like check for duplicates, check for gender or
check for batch clusters were performed (for details see
Stefansson et al.
42). 266.382 SNPs passed the quality
control in 1168 individuals with the following ﬁlters: (i)
individual call rate 495%, (ii) SNP call rate 499%, (iii)
minor allele frequency o0.01, (iv) deviation from Hardy–
Weinberg equilibrium in controls at Po10E-06. After
removing eight individuals, no population stratiﬁcation was
seen. For the chromosomal region of interest in this paper,
SNPs were selected between the positions (Chr 2: 17518961
and 17665665) covering eight SNPs. Only samples with a
call rate greater than 98% were included in the analysis. The
Hardy–Weinberg equilibrium was P40.05 in all SNPs and
subsamples.
Statistical analysis. Signiﬁcance of the neurite outgrowth
results was analyzed using Microsoft excel and Insat
software. Average neurite length was expressed as
mean±s.e. One-way analysis of variance was used to
evaluate signiﬁcant differences between treatment
conditions. Sociodemographic parameters such as w
2-,
t-tests or analysis of variance were used as appropriate.
For case–control studies, an additive model in PLINK was
used.
43 For analyses of WCST, the covariates ‘age’, ‘gender’
and ‘education’, as well as the ‘disease status’ in the whole
sample were included. Again, an additive model was
calculated. Haploview 4.0 (http://www.broad.mit.edu/mpg/
haploview/) was used to generate a linkage disequilibrium
map (r2 and D’, see Supplementary Figure 1). Tests for
associations using multimarker haplotypes were performed
using the software environment ‘R’ (http://www.R-
project.org). Global and single haplotype signiﬁcance and
odds ratios were calculated. Nominally signiﬁcant asymptotic
P-values were conﬁrmed by permuting the case–control
status over 10000 replicates to adjust for multiple testing and
observing the maximum test statistic in each case. To
compare quantitative traits between the haplotypes, the R
software package ‘haplo.score’ was used, integrating the
covariates sex, age, education and diagnosis as appropriate.
All nominally signiﬁcant P-values were conﬁrmed by
permuting over 10000 replicates and observing the
maximum test statistic (simulated P-value; sim.p).
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Association of VSNL1 SNPs with schizophrenia. Here
we report for the ﬁrst time, an association of SNPs in the
VSNL1 locus (protein name VILIP-1) with schizophrenia.
Two intergenic SNPs, rs394874 and rs424827, located on
chromosome 2p24.3 (17518961, 17577281), 50 of the VSNL1
gene encoding C/T and A/G polymorphisms, and all other
intragenic SNPs (rs650275, rs834504, rs1519477,
rs12470654, rs1033297 and rs11677051; chromosomal
location: 17623649, 17665665) showed signiﬁcant
association (P¼0.0080, P¼0.0097, P¼0.0178,
P¼0.0190, P¼0.0210, P¼0.0054, P¼0.0384 and
P¼0.0053, respectively, Table 1) with schizophrenia.
Regarding linkage disequilibrium, one block of all eight
SNPs was detected with high to moderate D’ (Supplementary
Figure 1). Haplotype analysis could further conﬁrm the case–
control results, showing one haploytpe with a higher
frequency in schizophrenia patients (CGTCTAAG,
frequency cases versus controls¼27.7 versus 24.0%,
w
2¼4.034, P¼0.0446) and the opposite protective
haplotype less frequent in patients (TACTCGGA, frequency
cases versus controls¼23.7 versus 28.2%, w
2¼6.155,
P¼0.0131, Table 2). These data identify VSNL1 as a
novel putative schizophrenia susceptibility gene.
Association of VSNL1 SNPs with WCST in
schizophrenia. The WCST measures higher executive,
so-called frontal lobe functions, and perseverative errors
have been shown to correlate positively with the occurrence
of schizophrenia.
34 For two of the intragenic SNPs,
rs12470654 and rs11677051, a replicated association for
the number of completed categories (controls/patients/
combined: rs11677051: P¼0.0029/P¼0.0321/P¼0.0003;
rs12470654: P¼0.0442/P¼0.0247/P¼0.0028), as well as
for the schizophrenia-speciﬁc perseverative error was found
in the WCST (rs11677051: P¼0.0095/P¼0.0180/
P¼0.0004; rs12470654: P¼0.0401/P¼0.0141/
P¼0.0012), with a lower performance in rs11677051 A-
carriers and in rs12470654 in G-carriers. To avoid multiple
testing problems, only associations, which replicated in both
groups with the same risk allele (healthy controls and
schizophrenia patients) as well as in the combined group,
are presented here (for all data see Supplementary Material,
Table 1). These results indicate that VSNL1 may be
implicated in cognition and speciﬁcally in frontal cortex-
dependent cognitive impairments in schizophrenia.
Effect of modulation of VILIP-1 expression on cAMP
signaling in hippocampal neurons. To look into the
possible biological signiﬁcance of the association of VSNL1
SNPs with the occurrence of schizophrenia, we evaluated the
possible effect of pathologically altered expression of its gene
product VILIP-1 on neuronal differentiation. We ﬁrst examined
localization of a heterologously expressed VILIP-1-GFP
construct in hippocampal neurons. Fluorescence micro-
scopy revealed localization throughout hippocampal neu-
rons in soma and all processes (Figures 1a and b).
Accumulation in some hot spots along neurites and presum-
ably neuritic growth cones is observed (Figure 1a, asterisks).
T
a
b
l
e
1
A
s
s
o
c
i
a
t
i
o
n
o
f
V
S
N
L
1
S
N
P
s
w
i
t
h
s
c
h
i
z
o
p
h
r
e
n
i
a
S
N
P
P
O
S
L
O
C
A
1
A
2
C
o
n
t
r
o
l
s
(
n
)
P
a
t
i
e
n
t
s
(
n
)
A
l
l
(
n
)
C
o
n
t
r
o
l
s
(
M
A
F
)
P
a
t
i
e
n
t
s
(
M
A
F
)
A
l
l
(
M
A
F
)
A
l
l
e
l
e
P
-
v
a
l
u
e
s
O
R
r
s
3
9
4
8
7
4
1
7
5
1
8
9
6
1
I
n
t
e
r
g
e
n
i
c
C
T
1
9
1
|
2
7
1
|
7
9
2
6
9
|
2
8
1
|
7
4
4
6
0
|
5
5
2
|
1
5
3
0
.
6
0
4
|
0
.
3
9
6
0
.
6
5
6
|
0
.
3
4
4
0
.
6
3
2
|
0
.
3
6
8
T
0
.
0
0
8
0
0
.
7
9
3
4
r
s
4
2
4
8
2
7
1
7
5
7
7
2
8
1
I
n
t
e
r
g
e
n
i
c
A
G
7
8
|
2
7
2
|
1
9
1
7
2
|
2
8
8
|
2
6
7
1
5
0
|
5
6
0
|
4
5
8
0
.
3
9
6
|
0
.
6
0
4
0
.
3
4
4
|
0
.
6
5
6
0
.
3
6
8
|
0
.
6
3
2
A
0
.
0
0
9
7
0
.
7
9
7
r
s
6
5
0
2
7
5
1
7
5
8
6
1
3
5
V
S
N
L
1
C
T
3
0
1
|
2
0
3
|
3
7
3
0
5
|
2
6
6
|
5
5
6
0
6
|
4
6
9
|
9
2
0
.
7
4
4
|
0
.
2
5
6
0
.
7
|
0
.
3
0
.
7
2
|
0
.
2
8
T
0
.
0
1
7
8
1
.
2
4
7
r
s
8
3
4
5
0
4
1
7
5
8
8
7
5
6
V
S
N
L
1
C
T
3
7
|
2
0
3
|
3
0
1
5
5
|
2
6
6
|
3
0
6
9
2
|
4
6
9
|
6
0
7
0
.
2
5
6
|
0
.
7
4
4
0
.
3
|
0
.
7
0
.
2
8
|
0
.
7
2
C
0
.
0
1
9
0
1
.
2
4
4
r
s
1
5
1
9
4
7
7
1
7
5
9
2
7
9
6
V
S
N
L
1
C
T
3
0
1
|
2
0
3
|
3
7
3
0
6
|
2
6
7
|
5
4
6
0
7
|
4
7
0
|
9
1
0
.
7
4
4
|
0
.
2
5
6
0
.
7
0
1
|
0
.
2
9
9
0
.
7
2
1
|
0
.
2
7
9
T
0
.
0
2
1
0
1
.
2
4
r
s
1
2
4
7
0
6
5
4
1
7
6
2
3
6
4
9
V
S
N
L
1
A
G
1
8
8
|
2
7
0
|
8
3
2
6
4
|
2
9
0
|
7
3
4
5
2
|
5
6
0
|
1
5
6
0
.
5
9
7
|
0
.
4
0
3
0
.
6
5
2
|
0
.
3
4
8
0
.
6
2
7
|
0
.
3
7
3
G
0
.
0
0
5
4
0
.
7
8
4
4
r
s
1
0
3
3
2
9
7
1
7
6
3
2
0
9
3
V
S
N
L
1
A
G
3
5
|
1
9
4
|
3
1
2
5
1
|
2
5
2
|
3
2
4
8
6
|
4
4
6
|
6
3
6
0
.
2
4
4
|
0
.
7
5
6
0
.
2
8
2
|
0
.
7
1
8
0
.
2
6
5
|
0
.
7
3
5
A
0
.
0
3
8
4
1
.
2
1
5
r
s
1
1
6
7
7
0
5
1
1
7
6
6
5
6
6
5
V
S
N
L
1
A
G
6
3
|
2
2
4
|
2
5
2
4
4
|
2
5
2
|
3
3
1
1
0
7
|
4
7
6
|
5
8
3
0
.
3
2
5
|
0
.
6
7
5
0
.
2
7
1
|
0
.
7
2
9
0
.
2
9
6
|
0
.
7
0
4
A
0
.
0
0
5
3
0
.
7
7
7
1
A
b
b
r
e
v
i
a
t
i
o
n
s
:
S
N
P
,
s
i
n
g
l
e
-
n
u
c
l
e
o
t
i
d
e
p
o
l
y
m
o
r
p
h
i
s
m
;
P
O
S
,
p
o
s
i
t
i
o
n
o
f
t
h
e
S
N
P
o
n
t
h
e
c
h
r
o
m
o
s
o
m
e
;
L
O
C
,
l
o
c
a
t
i
o
n
o
f
t
h
e
S
N
P
o
n
t
h
e
c
h
r
o
m
o
s
o
m
e
;
A
1
,
A
2
,
a
l
l
e
l
e
s
1
a
n
d
2
;
n
,
n
u
m
b
e
r
o
f
c
o
n
t
r
o
l
s
,
p
a
t
i
e
n
t
s
a
n
d
t
h
e
c
o
m
b
i
n
e
d
g
r
o
u
p
;
M
A
F
,
m
i
n
o
r
a
l
l
e
l
e
f
r
e
q
u
e
n
c
y
.
P
-
v
a
l
u
e
f
o
r
c
a
s
e
–
c
o
n
t
r
o
l
c
o
m
p
a
r
i
s
o
n
u
n
d
e
r
t
h
e
a
d
d
i
t
i
v
e
m
o
d
e
l
.
VSNL1 and schizophrenia
KH Braunewell et al
4
Translational PsychiatryCostaining with the dendritic marker microtubule-associated
protein 2 reveals that VILIP-1 is present in dendrites as
well as in microtubule-associated protein 2-negative, axonal
extensions (Figure 1b), similar to our previous observations.
35
To test whether VILIP-1-GFP expression may affect
neuronal signaling and, in turn, neuronal differentiation of
hippocampal neurons, we transfected E19 hippocampal
neurons before differentiation in vitro with GFP-VILIP-1 and
knocked down expression with VILIP-1 siRNA, and monitored
expression by western blot analysis (Figures 1c and d).
VILIP-1-GFP transfection produced an additional VILIP-1-
positive protein band at an molecular weight of 50kDa above
the endogenous 22-kDa band (Figure 1c), whereas VILIP-1
siRNA knockdown reduced the expression of endogenous
VILIP-1 by about 45% (Figures 1c and d). Next, the effect of
VILIP-1-GFP overexpression or VILIP-1 knockdown on
forskolin-stimulated adenylyl cyclase activity was evaluated
(Figure 1e). A signiﬁcant increase of cAMP levels following
VILIP-1-GST transfection, and a decrease following siRNA
knockdown of VILIP-1 expression indicated that VILIP-1
affects cAMP signaling in hippocampal neurons.
Table 2 Association of VSNL1 SNP haplotypes with schizophrenia
Block Frequencies (%)
cases, controls
v
2-test P-values
CGCTCAGG 0.327, 0.311 0.711 0.3991
CGTCTAAG 0.277, 0.240 4.034 0.0446
TACTCGGA 0.237, 0.282 6.155 0.0131
TACTCGGG 0.086, 0.088 0.010 0.9206
CGCTCGGA 0.022, 0.031 2.114 0.1460
TACTCAGG 0.018, 0.023 0.670 0.4129
CGTCTAGG 0.018, 0.013 1.040 0.3079
Abbreviations: SNP, single-nucleotide polymorphisms; VSNL1, visinin-like 1.
Haplotypes of the eight studied SNPs and their P-values for case–control
association are presented. Haplotypes with a frequency o1% were excluded.
Signiﬁcant haplotypes are in bold.
Figure 1 Visinin-like-protein-1 (VILIP-1)-green ﬂuorescent protein (GFP) overexpression and small interfering RNA (siRNA) knockdown of endogenous VILIP-1
expression in hippocampal neurons. (a) Fluorescence detection of VILIP-1-GFP expression in two neighboring hippocampal neurons in culture. Note, hot spots of expression
in ﬁne neuritic extensions and growth cones (asterisks). (b) Localization of VILIP-1-GFP in axons and dendrites in VILIP-1-GFP-transfected (green) and non-transfected
neuronscostainedwiththedendriticmarkermicrotubule-associatedprotein2(red).Note,co-staininginyellowisseenindendriticstructures(arrowheads),whereasonlygreen
ﬂuorescence representsVILIP-1-GFPexpressioninaxons (arrows).(c)Western blot analysismonitoringendogenousandVILIP-1-GFPoverexpression (V1-GFP)andsiRNA
knockdown of endogenous VILIP-1 expression in hippocampal neurons. Immunostaining of actin serves as loading control. (d) Quantiﬁcation of the effect of VILIP-1 siRNA
knockdown (siRNA) of endogenous VILIP-1expression. (e)Effect of VILIP-1-GFP overexpression (V1-GFP)compared with GFPcontrol(empty), andof siRNA knockdown of
endogenousVILIP-1(siRNA)comparedwithscrambledsiRNAcontrol(scr)onforskolin-inducedcAMP-accumulationinhippocampalneurons.Meanvaluesfromatleastthree
independent experiments (n¼3) are shown and error bars indicate s.d. Asterisks indicate signiﬁcant (*) and highly signiﬁcant (***) differences of the mean values.
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Translational PsychiatryEffect of modulation of VILIP-1 expression on
morphological differentiation of hippocampal
neurons. When hippocampal cultures transfected with
VILIP-1-GFP and GFP vector alone were compared,
obvious changes in neuronal morphology of transfected
cells were observed 48h following transfection (Figures 2a
and b). Compared with GFP control transfection, VILIP-1-
GFP transfection led to a noticeable stronger differentiation
with a higher degree of branching (Figure 2, compare A with
B). For quantiﬁcation purposes, we aimed to identify the
transfected neurons only, as hippocampal neurons show
relatively low transfection efﬁciences. Therefore, we co-
transfected a GFP construct with siRNA against VILIP-1 or
the control siRNA (Figures 2c and d). Only in the case of
GFP-co-transfected neurons containing VILIP-1 siRNA, the
expression of endogenous VILIP-1 was diminished
(Figure 2c) compared with GFP/control siRNA co-trans-
fected neurons (Figure 2d), as revealed by co-immuno-
staining against VILIP-1 protein (in red). Quantiﬁcation of
transfected hippocampal neurons was performed by Sholl
analysis, which is a simple and established tool to
characterize the morphological characteristics of neurons.
44
Fluorescence images from GFP, VILIP-1-GFP, GFP/VILIP-1
siRNA and GFP/control siRNA-co-transfected hippocampal
neuronal cultures, we analyzed using the half-automatic
Sholl–Plugin for NIH ImageJ software. The number of
dendrite intersections of concentric circles around the center
of the cell soma was counted in gradually increasing radii from
20 to 100mm (Figure 3a). Overexpression of VILIP-1-GFP
leads to increased number of dendritic arborization close to
Figure 2 Effect of visinin-like-protein-1 (VILIP-1)-green ﬂuorescent protein(GFP) on neuronalmorphologyand silencingof VILIP-1 expression with small interferingRNA
(siRNA) in hippocampal cultures. (a and b) Examples of dendritic morphologies of GFP (a) versus VILIP-1-GFP (b) transfected hippocampal neurons 48h following
transfection.BarinBis50mm.(candd)SilencingofVILIP-1expressioninhippocampalcultureswithsiRNA.ConfocalﬂuorescencepicturesGFP(green)andanti-VILIP-1-or
control-siRNA co-transfected (after 1 div) hippocampal neurons (3 div) immunostained with anti-VILIP-1/Cy3 antibodies (red). (c) Shows anti-VILIP-1-siRNA-transfected,
whereas (d) shows control-siRNA-transfected hippocampal neurons. The ﬁrst column shows the green GFP channel, column 2 the red immunostaining channel for VILIP-1/
Cy3, and column 3 depicts the overlay of channel 1 and 2. Regions of colocalization of immunoﬂuorescence appear yellow. Bars are 50mm.
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Translational Psychiatrythe soma (Figures 3b and c). The greatest effect of VILIP-1
expression is observed at 30mm distance from the soma
center when all neurons were analyzed (Figure 3b) and in
neurons with typical pyramidal morphology (Figure 3c).
When treatment with siRNA against VILIP-1 was compared
with control siRNA treatment, signiﬁcant differences in
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Figure 3 Effect of visinin-like-protein-1 (VILIP-1) expression and cyclic adenosine monophosphate (cAMP) signaling on branching in hippocampal neurons. (a)
Exempliﬁcation of the Sholl analysis showing counting of neurites in concentric rings (20–100mm) around the cell soma of a hippocampal neuron as a measure for dendritic
arborization. Bar in A is 50mm. (b) Effect of VILIP-1-green ﬂuorescent protein (GFP) overexpression (VILIP-1) on the number of dendrites in the distance from 20 to 100mm
from the cell soma in all neurons. (c) Effect of VILIP-1-GFP overexpression on the number of dendrites in the distance from 20 to 100mm from the cell soma in pyramidal
neurons. (d) Effect of VILIP-1-knockdown (VILIP-1) on the number of dendrites in the distance from 20 to 100mm from the cell soma in all neurons. (e) Effect of VILIP-1
knockdown on the number of dendrites in the distance from 20 to 100mm from the cell soma in pyramidal cells. (f) Summary of the effect of VILIP-1-GFP overexpression and
VILIP-1smallinterferingRNA(siRNA)knockdownonthenumberofdendritesin30mmdistancefromthesomacenterinallneurontypesandinpyramidalneurons.Datawere
from100neurons(25for pyramidalneurons)pergroupoutof threeexperiments.Asterisksindicatesigniﬁcant(*), highsigniﬁcant(**),andhighlysigniﬁcant(***)differencesof
themeanvalues.(g-l)EffectofenhancedandreducedcAMP-signaling,andcAMP-dependenteffectofVILIP-1onbranchinginhippocampalneurons.(g)Effectofforskolinon
thenumberofdendritesinthedistancefrom20to100mmfromthecellsomainallneuronscomparedwithcontrol.(h)Effectof H89and20,50-dideoxyadenosine(DDA)onthe
number of dendrites in the distance from 20 to 100mm from the cell soma compared with control. (i) Summary effect of DDA and H89 on the number of dendrites in the
distance from 20 to 100mm from the cell soma in hippocampal neurons compared with control. (j) Effect of H89 on the VILIP-1-GFP-dependent increase in the number of
dendrites in the distance from 20 to 100mm from the cell soma in all neurons. (k) Effect of DDA on VILIP-1-GFP-dependent increase in number of dendrites in the distance
from 20 to 100mm from cell soma in all neurons. (l) Summary of the effect of DDA and H89 treatment on the VILIP-1-GFP-dependent increases in the number of dendrites in
the distance from 20 to 100mm from the cell soma in all neurons. Data were from 100 neurons (25 for pyramidal neurons) per group out of three experiments.
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Translational Psychiatrydendritic morphology was observed over a wider range of
distance. VILIP-1 led to a signiﬁcant decrease in the number
of dendrites between 20 and 60mm distance from the cell
soma in all neurons and in neurons with pyramidal phenotype
(Figures 3d and e). Quantiﬁcation of the data at 30mm
distance from the soma center showed a signiﬁcant increase
of 13% when all neurons were analyzed and a 21% increase
in neurons with typical pyramidal morphology following
VILIP-1-GFP transfection. siRNA for VILIP-1 produced 20%
decrease in neurite number in all neurons versus 27%
decrease for pyramidal cells (Figure 3f). These results
indicate that VILIP-1 overexpression leads to formation of
novel neurites close to the soma, whereas reduced VILIP-1
expression leads to a general reduction in the number of
neurites at all distances from the soma.
Effect of VILIP-1 expression on morphological
differentiation of hippocampal neurons depends on
cAMP signaling. Next, we analyzed the causal correlation
between the effect of VILIP-1 on cAMP production and its
effect on dendritic arborization. As control treatment to show
that cAMP affects neurite growth in the hippocampal culture
system, forskolin was applied to enhance cAMP
accumulation, and the general adenylyl cyclase inhibitor
DDA and the protein kinase A inhibitor H89 were applied to
reduce cAMP signaling in hippocampal neurons. As
expected, these treatments led to enhancement and
reduction of the number of dendrites, respectively (Figures
3g and h). Quantiﬁcation of the effect revealed that the two
inhibitors, H89 and DDA, signiﬁcantly reduced neurite
outgrowth by 25 and 35%, respectively (Figure 3i). When
VILIP-1-GFP-transfected hippocampal cultures were treated
with the two inhibitors of the cAMP pathway, DDA and H89,
the VILIP-1-dependent increase in number of dendrites was
completely abolished (Figures 3j and k). Quantiﬁcation of the
effect revealed that the inhibitors signiﬁcantly reduced the
VILIP-1-dependent enhancement of dendritic growth to
background levels (Figure 3l). Thus, the effect of VILIP-1
on formation of new dendritic processes depends on
increased cAMP levels.
Overexpression and siRNA knockdown of VILIP-1 in SH-
SY5Y neurons and effect on cAMP signaling. The human
neuronal cell line SH-SY5Y has been used as a cellular
model for schizophrenia, in which growth factors implicated
in schizophrenia lead to the regulation of schizophrenia
susceptibility genes such as VSNL1.
27 Therefore, we have
tested the effect of VILIP-1 on neuronal morphology of SH-
SY5Y cells. VILIP-1-GFP expression in SH-SY5Y neurons
was shown to be present in axonal as well as dendritic
neurites, as revealed by co-staining with the axonal marker
SMI-312 (Figures 4a and b). Often, VILIP-1 was found to be
enriched in growth cones of dendrites and axons (Figures 4a
and c, asterisks). The overexpression of VILIP-1-GFP in SH-
SY5Y neurons produced an additional VILIP-1-positive
protein band at a molecular weight of 50kDa above the
22-kDa endogenous protein band (Figure 4a), whereas
VILIP-1 siRNA knockdown reduced the expression of
endogenous VILIP-1 by 65% (Figures 4a and e). Moreover,
VILIP-1-GFP overexpression has a signiﬁcant effect on
forskolin-stimulated cAMP accumulation, when compared
with GFP-control-transfected neurons (Figure 4f). Signiﬁ-
cantly decreased cAMP levels were observed following
siRNA knockdown of VILIP-1 expression (Figure 4g). These
results indicate that VILIP-1 affects cAMP accumulation in the
human neuronal cell line SH-SY5Y.
Effect of modulation of VILIP-1 expression and cAMP
signaling on morphological differentiation of SH-SY5Y
neurons. For evaluating the effect of VILIP-1 on dendritic
growth, we transfected SH-SY-5Y cells with either GFP
vector and VILIP-1-GFP, or with control siRNA and siRNA for
VILIP-1, and quantiﬁed differences in number and average
length of neurites, assuming that with only one axon per
neuron, neurites will be mainly of dendritic origin (Figures
4a–c). VILIP-1-GFP overexpression (Figure 5, compare b
with a) produces an increase, whereas siRNA treatment
(Figure 5, compare d with c) leads to reduction in number
and length of neurites as revealed by quantiﬁcation of the
average neurite length (Figure 5e). In addition, we used
different chemicals, which are either activators or inhibitors of
the cAMP signal pathway, to understand the exact
mechanism by which VILIP-1 exerts its effects. The general
inhibitor of adenylyl cyclases DDA and the protein kinase A
inhibitor KT5720 were able to attenuate the VILIP-1 effect on
neurite length in nerve growth factor-treated SH-SY5Y cells
(Figure 5e). DDA reduced the average neurite length below
control levels, which indicate that other factors besides
VILIP-1 contribute to cAMP-dependent neurite extension in
nerve growth factor-treated neurons. When additional
parameters were analyzed, the number of branch points
showed an even more pronounced effect. VILIP-1 increases
dendrite branching by more than 100% (Figure 5f).
Moreover, VILIP-1 seems to strongly induce formation of
ﬁlopodia (Figure 5g). The examples show that in comparison
with GFP-transfected SH-SY5Y cells, VILIP-1-GFP-
transfected neurons show extensive branching, never
observed in control cultures. Following quantiﬁcation, a
100% increase in the number of neurons with extensive
ﬁlopodia formation is observed (Figure 5h), indicating that
VILIP-1 may particularly affect initial formation of ﬁlopodia,
which typically proceeds neurite formation and dendritic
branching.
Discussion
In this study, we have examined a set of SNPs located
intragenic and intergenic (50) of the VSNL1 gene for
association with the occurrence of schizophrenia in a cohort
of patients and controls.
38,42 We have identiﬁed signiﬁcant
association of two intergenic and six intragenic SNPs with
schizophrenia, and two of the intragenic SNPs signiﬁcantly
associated with the WCST.
41 For WCST, only replicated
SNPs that were associated in cases only, in controls only and
in the combined group with the same risk allele are high-
lighted. The WCST is used to assess higher cognitive
functions, so-called executive functions, such as strategic
planning, organized searching, utilizing environmental feed-
back to shift cognitive sets, directing behavior towards
achieving a goal and modulating impulsive responding.
34
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Translational PsychiatryThe common test relies upon a number of intact cognitive
functions including attention, working memory and visual
processing. WCST perseverative errors have been shown to
correlate positively with lesions of the dorsolateral frontal lobe
and schizophrenia, suggesting that deﬁciencies in conceptual
organization and ﬂexibility in abstract thinking occur in
patients.
45 In this study, the relationship between the selected
SNPs in the VSNL1 gene and cognitive set-shifting as
measured by perseverative errors using the WCST was
tested. The results indicate an association of cognitive
ﬂexibility and frontally based executive function with VSNL1
SNPs. However, it is noteworthy that counterintuitively the
associated risk alleles for schizophrenia are associated with a
better performance in the WCST. Although this ﬁnding may
have been a surprise, similar results have also been
presented; for example, for one of the best replicated risk
genes for schizophrenia (ZNF804A) there, the schizophrenia
allele was associated with better and not lower cognitive
performance.
46 Our results are therefore potentially important
to our understanding of the genetic mechanisms and path-
ways that contribute to the susceptibility, as little is known
about the function of VSNL1. The aim of our study was
therefore to further characterize the functionality of this gene.
Especially,asschizophreniaisaveryheterogeneousdisorder
with several subtypes, it is perhaps possible that not all
identiﬁed susceptibility alleles will have majoreffects on broad
cognitive abilities and that, not all schizophrenia risk alleles
will associate with all intermediate phenotypes in further
functional studies.
Nevertheless, our results may hint towards an impact of
VSNL1 SNPs and also of altered expression of VILIP-1 in
schizophrenia on certain aspects of cognition. It is noteworthy
in this context that VILIP-1 was identiﬁed as a cerebrospinal
ﬂuid biomarker for Alzheimer’s disease with association of
VILIP-1 levels, with the severity of Alzheimer’s disease
and association with the Mini-Mental Statement Examina-
tion as a measure of cognitive impairment in Alzheimer’s
disease.
47,48 Future experiments will have to show whether
VILIP-1 expression is linked to speciﬁc cognitive distur-
bances, such as attention and/or memory impairment.
Our ﬁndings further raise the question of the biological
signiﬁcance of misregulated expression of the novel schizo-
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Figure 4 Visinin-like-protein-1 (VILIP-1)-green ﬂuorescent protein (GFP) localization in human SH-SY5Y neurons and effect of VILIP-1-GFP overexpression and small
interferingRNA(siRNA)knockdownofVILIP-1oncyclicadenosinemonophosphate(cAMP)accumulation.(a–c)Fluorescencepictureof(a)VILIP-1-GFPtransfectedneuron,
stainedwith(b)theaxonalmarkerSMI-312.ArrowindicatesaVILIP-1-GFP-andSMI-312-positiveaxon,whereasarrowheadsindicateVILIP-1-positive,butSMI-312-negative
dendrites. Asterisks show growth cones enriched with VILIP-1-GFP ﬂuorescence. (c) Example of VILIP-1-GFP-transfected SH-SY5Y neuron with long, probably axonal
structure and several dendritic-like neurites. Asterisks mark VILIP-1-GFP enriched growth cones. Bar is 25mm. (d–g) Effect of VILIP-1-GFP overexpression and siRNA
knockdown of VILIP-1 on cAMP accumulation in SH-SY5Y neurons. (d) Western blot analysis monitoring VILIP-1-GFP overexpression and siRNA knockdown of VILIP-1.
Antibodies against VILIP-1 and against GFP stain endogenous VILIP-1 at 22kDa and a VILIP-1-GFP band at 45kDa, respectively. Actin immunostaining serves a loading
control.(e)Quantiﬁcationof siRNAknockdownof VILIP-1in SH-SY5Yneuronsas shownin(d).(f)Effect of transfection of SH-SY5Yneuronswith VILIP-1-GFPor GFPalone
on basal and forskolin-induced cAMP levels. (g) Effect of transfection of SH-SY5Y with either VILIP-1 siRNA control or VILIP-1 siRNA on basal and forskolin-induced cAMP
levels.Meanvaluesfromatleastthreeindependentexperiments(n¼3)areshownanderrorbarsindicates.d.Asterisksindicatesigniﬁcant(*)differencesofthemeanvalues.
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Translational Psychiatryphrenia susceptibility factor VILIP-1 during development,
which may lead to structural and ﬁnally cognitive disturbances
in affected brain regions. Therefore, we started to investigate
whether upregulation and/or downregulation of VILIP-1
expression during development affect neuronal differentia-
tion, and thus possibly lead to pathological changes in
dendritic and axonal structures, which could contribute to
developmental disturbances during the course of the dis-
ease.
4,5 Interestingly, the schizophrenia susceptibility gene
Disc1 has recently been shown to have an effect on neuronal
differentiation in that it enhances neurite outgrowth.
14 Disc1 is
a physiological binding partner of PDE4, a cAMP-speciﬁc
phosphodiesterase, thus potentially affecting the cAMP
signaling pathway.
15 Previously, VILIP-1 has been shown to
affect cAMP-signaling in several heterologous expression
systems.
19,20 Reduced cAMP and increased rho-signaling
lead to reduced branching of dendritic structures and are both
important signaling system for neuronal differentiation.
15,49
Thus, we have investigated the role of VILIP-1 in conjunction
with cAMP-signaling for differentiation of hippocampal neu-
rons and human SH-SY5Y neuronal cells, frequently serving
as a cellular model for schizophrenia.
26,27 We were able to
show for the ﬁrst time that VILIP-1 affects cAMP signaling in
neuronal cells, and thereby affects cAMP-dependent mor-
phology of neurons. Indeed, cAMP is a well-known promoter
of neurite plasticity and branching.
15,33,36,37 However, addi-
tional pathways regulating the ﬁne tuning of axonal versus
dendritic differentiation and outgrowth, such as GAP43, rhoA
and the PIP2/PI3K/AKT/GSK3b pathway also have to be
taken into account.
49–53
One of the main characteristics of neurons is their shape,
with every neuron extending long-branched dendrites to
create a complex wiring network. Creation of such neuronal
network has a central role in neuronal transmission and
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Figure 5 Effect of visinin-like-protein-1 (VILIP-1) expression and cyclic adenosine mono phosphate (cAMP) signaling on neurite outgrowth in nerve growth factor (NGF)-
treated human SH-SY5Y neurons. (a–c) Phase contrast images of SH-SY5Y neurons transfected with VILIP-1-green ﬂuorescent protein (GFP) (a), GFP (b), VILIP-1 small
interfering RNA (siRNA) (c) and siRNA control (d). (e) Quantiﬁcation of the effect of VILIP-1- and cAMP signaling on average neurite length of NGF-treated human SH-SY5Y
cells. Neurons were treated with VILIP-1 and control siRNA, transfected with GFP and VILIP-1-GFP, and transfected with VILIP-1-GFP and treated with adenylyl cyclase
inhibitor20,50-dideoxyadenosine(DDA)orproteinkinaseAinhibitorKT5720.(f)EffectofVILIP-1-GFPtransfectiononaveragenumberofbranchpointsinNGF-treatedhuman
SH-SY5Yneurons.Mean valuesfromat leastthreeindependentexperiments(n¼3) are shownand error bars indicates.d. Asterisksindicatesigniﬁcant(*) differencesof the
mean values. Bars are 25mm. (g) Example of a neuron extending high numbers of ﬁlopodia in NGF-treated VILIP-1-GFP-transfected human SH-SY5Y neurons. (h)
Quantiﬁcation of the number of neurons with ﬁlopodia in GFP- versus VILIP-1-GFP-transfected cells. Mean values were from at least three independent experiments (n¼3)
and error bars indicate s.d.. Asterisks indicate signiﬁcant (*) differences of the mean values. Bar is 25mm.
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Translational Psychiatrycentral nervous system function. VILIP-1-GFP led to en-
hanced branching, particularly in short distance from the
soma in hippocampal neurons. Similarly, in SH-SY5Y
neurons, VILIP-1 strongly induced formation of ﬁlopodia and
branching. Both results indicate that VILIP-1 might affect
already the initial phase of neuritogenesis and branching
by enhancing the formation of new ﬁlopodia. During
early development, ﬁlopodia can be transformed into
dendritic branches, whereas later in development, ﬁlopodial
protrusions can develop into dendritic spines.
54,55 Thus, it
appears likely that changed expression of VILIP-1 during
development of the brain, depending on increased or
decreased expression, may positively or negatively affect
neuronal outgrowth and particularly, dendritic branching. The
elaboration of complex dendritic arbors during development
are necessary to integrate synaptic inputs and thus determine
proper neuronal network activity.
56 However, it also has been
suggested that behavioral symptoms of schizophrenia could
arise from over pruning or failed maintenance of dendrites
later in life, occurring before and during psychosis develop-
ment in schizophrenia in late adolescence.
57 It is noteworthy
in this context that the modulation of VILIP-1 expression has
already been shown to affect neuronal network activity by
affecting nicotinergic modulation of GABAergic activity of
interneurons in hippocampal cultures.
23 Observed pathologi-
cal changes in expression levels, up- or downregulation
in schizophrenia, for instance as reported in certain
types of hippocampal interneurons and in the nucleus
accumbens,
22–26 might lead to pathological dendritic mor-
phology of key neuronal subtypes. We hypothesize that this
may contribute to subtle changes in neuronal connectivity,
leadingtosomeofthecognitivedeﬁcitstypicallymeasuredvia
tests such as WCST.
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